AU2018285821B2 - Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia - Google Patents

Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia Download PDF

Info

Publication number
AU2018285821B2
AU2018285821B2 AU2018285821A AU2018285821A AU2018285821B2 AU 2018285821 B2 AU2018285821 B2 AU 2018285821B2 AU 2018285821 A AU2018285821 A AU 2018285821A AU 2018285821 A AU2018285821 A AU 2018285821A AU 2018285821 B2 AU2018285821 B2 AU 2018285821B2
Authority
AU
Australia
Prior art keywords
pll
tinostamustine
pharmaceutically acceptable
acceptable salt
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018285821A
Other languages
English (en)
Other versions
AU2018285821A1 (en
Inventor
Marco HERLING
Thomas Jorg MEHRLING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of AU2018285821A1 publication Critical patent/AU2018285821A1/en
Application granted granted Critical
Publication of AU2018285821B2 publication Critical patent/AU2018285821B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018285821A 2017-06-13 2018-06-13 Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia Active AU2018285821B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1709402.0 2017-06-13
GBGB1709402.0A GB201709402D0 (en) 2017-06-13 2017-06-13 Compounds for treating t-pll
PCT/EP2018/065664 WO2018229132A1 (en) 2017-06-13 2018-06-13 Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia

Publications (2)

Publication Number Publication Date
AU2018285821A1 AU2018285821A1 (en) 2019-12-19
AU2018285821B2 true AU2018285821B2 (en) 2024-07-04

Family

ID=59358363

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018285821A Active AU2018285821B2 (en) 2017-06-13 2018-06-13 Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia

Country Status (14)

Country Link
US (4) US11318117B2 (enExample)
EP (1) EP3638231B1 (enExample)
JP (1) JP7195283B2 (enExample)
KR (1) KR102655833B1 (enExample)
AR (1) AR112101A1 (enExample)
AU (1) AU2018285821B2 (enExample)
BR (1) BR112019026484A2 (enExample)
CA (1) CA3067276A1 (enExample)
ES (1) ES2966954T3 (enExample)
GB (1) GB201709402D0 (enExample)
IL (1) IL271017A (enExample)
MX (1) MX392103B (enExample)
TW (1) TW201919616A (enExample)
WO (1) WO2018229132A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
EP3897626B1 (en) * 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma
CA3149796A1 (en) * 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US20020076409A1 (en) 2000-07-12 2002-06-20 March Carl J. Method for treating cancer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
CN1764648A (zh) 2003-01-13 2006-04-26 安斯泰来制药有限公司 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
EP1599449A2 (en) 2003-02-25 2005-11-30 TopoTarget UK Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
US20060270730A1 (en) 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CA2561617A1 (en) 2004-04-05 2005-10-20 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
SI1901729T1 (sl) 2005-05-13 2012-05-31 Topotarget Uk Ltd Farmacevtske formulacije HDAC inhibitorjev
NZ575394A (en) 2006-10-20 2012-01-12 Icos Corp Compositions of chk1 inhibitors and cyclodextrin
GB0621160D0 (en) 2006-10-24 2006-12-06 Imp College Innovations Ltd Compounds and uses thereof
WO2008063644A1 (en) 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
CN101084876A (zh) 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009067453A1 (en) 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
US8987468B2 (en) 2008-02-04 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
CN104224703A (zh) 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
MX2011003751A (es) 2008-10-08 2011-04-27 Cephalon Inc Procesos para preparar bendamustina.
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
ME02254B (me) 2009-01-23 2015-12-31 Euro Celtique Sa Derivati hidroksamske kiseline
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2011017448A1 (en) 2009-08-05 2011-02-10 The Trustees Of The University Of Pennsylvania Use of histone deacetylase inhibitors for treatment of autoimmune diseases
CN101928234B (zh) 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
US9889147B2 (en) 2010-04-16 2018-02-13 Cellact Pharma Gmbh Analogues of etoposide for the treatment of tumours
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US8748470B2 (en) 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
CN102993102B (zh) 2011-09-16 2016-08-24 杭州民生药业有限公司 [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法
EP2758052B9 (en) 2011-09-18 2019-03-27 Euro-Celtique S.A. Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
ES2616242T3 (es) 2011-09-28 2017-06-12 Euro-Celtique S.A. Derivados de mostaza de nitrógeno
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
NZ630314A (en) 2014-02-18 2016-03-31 Celgene Corp Combination therapy for hematological malignancies
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
CN107438436A (zh) 2014-12-05 2017-12-05 摩德纳和雷焦艾米利亚大学 用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合
US20180311215A1 (en) 2015-10-20 2018-11-01 Hangzhou TINO Pharma Co., Ltd. Pharmaceutical composition and preparation method therefor
US20180098969A1 (en) 2016-10-11 2018-04-12 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
EP3897626B1 (en) 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma

Also Published As

Publication number Publication date
CA3067276A1 (en) 2018-12-20
JP2020523359A (ja) 2020-08-06
KR20200015563A (ko) 2020-02-12
TW201919616A (zh) 2019-06-01
EP3638231C0 (en) 2023-12-20
US20220401417A1 (en) 2022-12-22
MX2019015208A (es) 2022-05-03
AR112101A1 (es) 2019-09-18
EP3638231A1 (en) 2020-04-22
ES2966954T3 (es) 2024-04-25
US12370178B2 (en) 2025-07-29
MX392103B (es) 2025-03-21
US20260083707A1 (en) 2026-03-26
US20200113871A1 (en) 2020-04-16
US20240316009A1 (en) 2024-09-26
AU2018285821A1 (en) 2019-12-19
US11318117B2 (en) 2022-05-03
US11918558B2 (en) 2024-03-05
GB201709402D0 (en) 2017-07-26
IL271017A (en) 2020-01-30
JP7195283B2 (ja) 2022-12-23
KR102655833B1 (ko) 2024-04-08
EP3638231B1 (en) 2023-12-20
BR112019026484A2 (pt) 2020-07-14
WO2018229132A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
US12370178B2 (en) Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia
CN103501785B (zh) 用于治疗脑肿瘤的csf-1r抑制剂
US11337983B2 (en) Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
WO2015154065A1 (en) Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination
JP6453441B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
KR20200014790A (ko) 난소암의 치료에 사용되는 티노스타무스틴
JP7235259B2 (ja) Ｇｖｈｄ又は腫瘍を治療するための骨髄系由来サプレッサー細胞のインフラマソーム活性化の調節
EP3220908B1 (en) Compositions and methods for treating endometriosis
US20230414642A1 (en) Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
WO2022100535A1 (zh) 一种抗肿瘤药物组合物及其应用
AU2016340017B2 (en) Compositions and methods for the treatment of diseases involving mucin
US20240025959A1 (en) Beclin 2 and uses thereof for treating cancer and neurodegenerative diseases
Yang et al. The novel B-cell epitope peptide vaccine, MAX449, exhibits significant anti-tumor efficacy and enhances the therapeutic effects of PD-1 antibodies on tumors by modulating the activity of PMN-MDSCs
WO2020092845A1 (en) Method and composition embodiments for treating acute myeloid leukemia
TW202022113A (zh) 葡萄糖苷基腦醯胺合成酶基因缺陷t細胞之用途及其治療上之應用
US20220347180A1 (en) Enhancing cancer therapy treatment with bh3 mimetics

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)